as 05-20-2024 3:33pm EST
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Founded: | 1999 | Country: | United States |
Employees: | N/A | City: | JERSEY CITY |
Market Cap: | 73.3M | IPO Year: | 2014 |
Target Price: | N/A | AVG Volume (30 days): | 228.7K |
Analyst Decision: | Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 2.04 | EPS Growth: | N/A |
52 Week Low/High: | $1.35 - $3.87 | Next Earning Date: | 05-08-2024 |
Revenue: | $140,385,000 | Revenue Growth: | 2436.77% |
Revenue Growth (this year): | -74.6% | Revenue Growth (next year): | -62.74% |
SCYX Breaking Stock News: Dive into SCYX Ticker-Specific Updates for Smart Investing
Associated Press Finance
12 days ago
GlobeNewswire
12 days ago
Simply Wall St.
12 days ago
GlobeNewswire
20 days ago
GlobeNewswire
a month ago
GlobeNewswire
2 months ago
GlobeNewswire
4 months ago
GlobeNewswire
4 months ago